FY2024 EPS Estimates for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Reduced by HC Wainwright

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – HC Wainwright lowered their FY2024 EPS estimates for shares of Arrowhead Pharmaceuticals in a report issued on Thursday, September 5th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings per share of ($4.71) for the year, down from their previous forecast of ($3.50). HC Wainwright currently has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($4.02) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q4 2024 earnings at ($1.09) EPS, Q1 2025 earnings at ($0.92) EPS, Q2 2025 earnings at ($0.92) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.84) EPS and FY2025 earnings at ($3.56) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.80). Arrowhead Pharmaceuticals had a negative return on equity of 152.95% and a negative net margin of 163.32%. During the same quarter last year, the firm earned ($0.96) earnings per share. Arrowhead Pharmaceuticals’s revenue for the quarter was down 100.0% on a year-over-year basis.

A number of other analysts have also issued reports on ARWR. B. Riley reiterated a “buy” rating and set a $55.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 12th. The Goldman Sachs Group assumed coverage on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, June 5th. They set a “neutral” rating and a $31.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Thursday, June 20th. Morgan Stanley dropped their price objective on shares of Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating on the stock in a research note on Monday, May 13th. Finally, Chardan Capital reiterated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, July 17th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.25.

Arrowhead Pharmaceuticals Stock Down 4.4 %

Shares of ARWR stock opened at $22.22 on Monday. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of -5.23 and a beta of 0.96. Arrowhead Pharmaceuticals has a fifty-two week low of $20.67 and a fifty-two week high of $39.83. The firm’s 50 day moving average price is $25.67 and its two-hundred day moving average price is $26.06.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ARWR. Fifth Third Bancorp raised its holdings in shares of Arrowhead Pharmaceuticals by 42.5% in the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 354 shares during the last quarter. Van ECK Associates Corp raised its holdings in shares of Arrowhead Pharmaceuticals by 22.9% in the fourth quarter. Van ECK Associates Corp now owns 2,395 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 447 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Arrowhead Pharmaceuticals by 2.4% in the second quarter. Arizona State Retirement System now owns 34,685 shares of the biotechnology company’s stock valued at $901,000 after buying an additional 821 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Arrowhead Pharmaceuticals by 12.3% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 8,714 shares of the biotechnology company’s stock valued at $279,000 after buying an additional 952 shares during the last quarter. Finally, Securian Asset Management Inc. raised its holdings in shares of Arrowhead Pharmaceuticals by 12.5% in the first quarter. Securian Asset Management Inc. now owns 10,100 shares of the biotechnology company’s stock valued at $289,000 after buying an additional 1,121 shares during the last quarter. 62.61% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Tracie Oliver sold 9,394 shares of the firm’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $25.28, for a total value of $237,480.32. Following the completion of the transaction, the insider now directly owns 127,107 shares of the company’s stock, valued at $3,213,264.96. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.50% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.